FDA Grants Traditional Approval for Selpercatinib for Medullary Thyroid Cancer with a RET Mutation By Ogkologos - November 6, 2024 808 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LIBRETTO-531 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Talazoparib Beyond BRCA Prospective Study Identifies the Sensitivity of gPALB2-Associated Breast... October 25, 2022 Rare Disease Day 2026: Advancing equity for people living with rare... February 27, 2026 6 Habits That Can Help You Feel More in Control of... November 30, 2022 Cure Probability Models for Evaluation of Patients with a Previous Cancer... October 26, 2021 Load more HOT NEWS The Grace Project Helps Breast Cancer Survivors Practice Body Acceptance and... FDA Approves Cemiplimab-rwlc for Locally Advanced and Metastatic Basal Cell Carcinoma 关于肺癌生物标志物检测应当了解的信息：专家问答 Biopsia por aspiración con aguja fina (PAAF): Cómo prepararse y qué...
